One form of treatment for MS patients used to date, which has been associated with simultaneous upregulation of IL-6 and IL-10, is therapy with glatiramer acetate (GA), a myelin basic protein (MBP) analogue approved by the Food Drug Association (FDA) [60,61]. The gene discussed is MBP; the disease is myeloid sarcoma.